Glofitamab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), HAS (France) and NICE (England), among others, recommended or restricted glofitamab, while NYE METODER (Norway) did not recommend it.
The record spans 2.9 years, opening at AWMSG (Wales) on 7 Sep 2023 and running to 23 Aug 2026.
DMC (Denmark) changed its position: not recommended on 28 Aug 2024, recommended by 24 Jun 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 25 of 26 records date from 2023 or later.
7 distinct indication wordings are recorded for glofitamab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 26 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess glofitamab, on 7 Sep 2023; PHARMAC (New Zealand) did not open a file until 17 Mar 2026 — a moderate spread of 2.5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 4 years in total.
Restriction is doing real work here: 5 of 19 decisive outcomes narrowed glofitamab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and SMC (Scotland) among others.
10 of the 13 agencies here assessed glofitamab more than once, CIPM (Spain) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
glofitamab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for glofitamab reads 8 recommended, 6 not recommended, 5 restricted and 4 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AIFA (Italy) | 7 Aug 2026 | Columvi in associazione con gemcitabina e oxaliplatino è indicato per il trattamento di pazienti adulti con linfoma diff… | innovative status not granted · reimbursed class H | source |
| SMC (Scotland) | 13 Jul 2026 | In combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise s… | accepted (restricted) | source |
| DMC (Denmark) | 24 Jun 2026 | Glofitamab i komb m. gemcitabin og oxaliplatin er indiceret til beh. af voksne med recidiverende eller refraktært diffus… | Anbefalet | source |
| HAS (France) | 18 Mar 2026 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PHARMAC (New Zealand) | 17 Mar 2026 | Diffuse large B-cell lymphoma, relapsed/refractory, transplant ineligible, 2nd line or later (with gemcitabine and oxali… | PTAC advice: High | source |
21 further decisions for glofitamab, across 12 agencies, are not shown here. They include the most recent record on file, 23 Aug 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- loncastuximab tesirine — divergent outcome (recommended vs not recommended) on a shared indication
- polatuzumab vedotin — divergent outcome (recommended vs not recommended) on a shared indication
- selinexor — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
Coverage: 26 decisions for glofitamab from 13 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.